Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

BackgroundImmune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy, improving outcomes in the treatment of various malignancies. However, not all patients benefit to the same extend from ICI. Reliable tools to predict treatment response and outcome are missing. Soluble urok...

Full description

Bibliographic Details
Main Authors: Sven H. Loosen, Joao Gorgulho, Markus S. Jördens, Maximilian Schulze-Hagen, Fabian Beier, Mihael Vucur, Anne T. Schneider, Christiane Koppe, Alexander Mertens, Jakob N. Kather, Frank Tacke, Verena Keitel, Tim H. Brümmendorf, Christoph Roderburg, Tom Luedde
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
immunotherapy
checkpoint inhibitors
prognosis
biomarker
nivolumab
pembrolizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.646883/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.646883/full

Similar Items